Literature DB >> 1674913

Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma.

Y Mizuno1, T Hara, M Nagata, A Tawa, T Tsuruo, K Ueda.   

Abstract

Flow cytometric detection of surface P-glycoprotein, a multidrug-resistant gene product, with a monoclonal antibody, MRK 16, was performed on cells obtained from 18 children with leukaemia and lymphoma. Of 18 patients examined, 1 with malignant lymphoma at relapse showed a significant increase in P-glycoprotein-positive cells and a strong resistance to chemotherapy. Overexpression of P-glycoprotein in a case with B-cell type malignant lymphoma was confirmed by immuno-precipitation and Northern hybridization analysis. The present study suggests that an increased expression of surface P-glycoprotein might be involved in multidrug resistance at least in a certain case of childhood leukaemia and lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674913     DOI: 10.1007/bf02093722

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

1.  Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.

Authors:  M Volm; M Bak; T Efferth; B Lathan; J Mattern
Journal:  Anticancer Res       Date:  1988 Jul-Aug       Impact factor: 2.480

2.  Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.

Authors:  P Ubezio; M Limonta; M D'Incalci; G Damia; G Masera; G Giudici; J S Wolverton; W T Beck
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

Review 3.  Multiple-drug resistance in human cancer.

Authors:  I Pastan; M Gottesman
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

4.  P-glycoprotein in acute nonlymphoblastic leukemia and in the blastic crisis of myeloid leukemia.

Authors:  G Carulli; M Petrini; A Marini; F Ambrogi
Journal:  N Engl J Med       Date:  1988-09-22       Impact factor: 91.245

5.  Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage.

Authors:  Y Ito; M Tanimoto; T Kumazawa; M Okumura; Y Morishima; R Ohno; H Saito
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

6.  Detection of P-glycoprotein in human leukemias using monoclonal antibodies.

Authors:  J Mattern; T Efferth; M Bak; A D Ho; M Volm
Journal:  Blut       Date:  1989-04

7.  Classification of chronic granulomatous disease on the basis of monoclonal antibody-defined surface cytochrome b deficiency.

Authors:  Y Mizuno; T Hara; M Nakamura; K Ueda; S Minakami; H Take
Journal:  J Pediatr       Date:  1988-09       Impact factor: 4.406

8.  Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia.

Authors:  M L Rothenberg; L A Mickley; D E Cole; F M Balis; T Tsuruo; D G Poplack; A T Fojo
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

9.  Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA, in human leukemia cells.

Authors:  T Tsuruo; Y Sugimoto; H Hamada; I Roninson; M Okumura; K Adachi; Y Morishima; R Ohno
Journal:  Jpn J Cancer Res       Date:  1987-12

10.  Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia.

Authors:  D D Ma; R D Scurr; R A Davey; S M Mackertich; D H Harman; G Dowden; J P Isbister; D R Bell
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

View more
  2 in total

1.  Flow cytometric analysis of P-glycoprotein in normal and leukemic cells.

Authors:  M I Tiirikainen; M T Syrjälä; S E Jansson; T Krusius
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

2.  In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Authors:  E Klumper; R Pieters; M L den Boer; D R Huismans; A H Loonen; A J Veerman
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.